{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-063124","form_type":"8-K","ticker":"ZBH","cik":"0001136869","company_name":"ZIMMER BIOMET HOLDINGS, INC.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.623881+00:00","generated_at":"2026-05-22T16:31:49.722590+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zimmer Biomet Q1 rev +1.1%; guides 2025 adj EPS down to $7.90-$8.10, rev up including Paragon 28","bullets":["Q1 net sales $1.909B (+1.1% reported, +2.3% CC); GAAP EPS $0.91, adjusted EPS $1.81.","2025 adjusted EPS guidance lowered to $7.90-$8.10 from $8.15-$8.35 due to Paragon 28, currency, and tariffs.","2025 reported revenue guidance raised to 5.7%-8.2% (includes Paragon 28); organic CC unchanged at 3%-5%.","Completed acquisition of Paragon 28 (foot and ankle orthopedics) in Q1 2025.","Chairman Begley retiring at May 29 meeting; CEO Tornos to become Chairman, Farrell Lead Independent Director."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-063124","json":"https://secwatch.observer/filing/0000950170-25-063124.json","markdown":"https://secwatch.observer/filing/0000950170-25-063124.md","text":"https://secwatch.observer/filing/0000950170-25-063124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1136869/000095017025063124/0000950170-25-063124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1136869/000095017025063124/zbh-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T16:31:49.722590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}